Viking Therapeutics Inc (1VT.MU)
| Previous close | 62.38 |
| Open | 61.52 |
| Bid | 60.12 x 0 |
| Ask | 60.88 x 0 |
| Day's range | 61.52 - 61.52 |
| 52-week range | 8.76 - 89.30 |
| Volume | |
| Avg. volume | 595 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireViking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.
ZacksViking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $71.67, indicating a -1.59% shift from the previous trading day.
Insider MonkeyWhat Makes Viking Therapeutics (VKTX) an Attractive Potential Opportunity?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The Strategy underperformed the benchmark in the quarter. The small-cap growth universe revealed a stark dichotomy despite the positive performance of the benchmark Russell 2000 Growth Index, which […]
